AI Article Synopsis
- The use of arsenic has shown success in degrading oncoproteins related to leukemia, highlighting the potential of inorganic compounds as anti-cancer agents.
- Inspired by this, researchers are studying the effects of inorganic selenium on a specific type of leukemia (t(8;21)), and have developed a selenium-based nanomedicine with promising results.
- The selenium targets leukemia cells by inducing their differentiation into mature myeloid cells and works by degrading the AML1-ETO oncoprotein, which regulates key genes involved in cancer progression.
Article Abstract
The success of arsenic in degrading PML-RARα oncoprotein illustrates the great anti-leukemia value of inorganics. Inspired by this, the therapeutic effect of inorganic selenium on t(8; 21) leukemia is studied, which has shown promising anti-cancer effects on solid tumors. A leukemia-targeting selenium nanomedicine is rationally built with bioengineered protein nanocage and is demonstrated to be an effective epigenetic drug for inducing the differentiation of t(8;21) leukemia. The selenium drug significantly induces the differentiation of t(8;21) leukemia cells into more mature myeloid cells. Mechanistic analysis shows that the selenium is metabolized into bioactive forms in cells, which drives the degradation of the AML1-ETO oncoprotein by inhibiting histone deacetylases activity, resulting in the regulation of AML1-ETO target genes. The regulation results in a significant increase in the expression levels of myeloid differentiation transcription factors PU.1 and C/EBPα, and a significant decrease in the expression level of C-KIT protein, a member of the type III receptor tyrosine kinase family. This study demonstrates that this protein-nanocaged selenium is a potential therapeutic drug against t(8;21) leukemia through epigenetic regulation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10724402 | PMC |
| http://dx.doi.org/10.1002/advs.202300698 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer.
Clin Cancer Res
February 2009
Department of Hematology-Oncology, National University Hospital, Oncology Research Institute, School of Computing, and Department of Head and Neck Surgery, National University of Singapore, Singapore.
Purpose: Cell cycle dysregulation resulting in expression of antiapoptotic genes and uncontrolled proliferation is a feature of undifferentiated nasopharyngeal carcinoma. The pharmacodynamic effects of seliciclib, a cyclin-dependent kinase (CDK) inhibitor, were studied in patients with nasopharyngeal carcinoma.
Experimental Design: Patients with treatment-naïve locally advanced nasopharyngeal carcinoma received seliciclib at 800 mg or 400 mg twice daily on days 1 to 3 and 8 to 12.
Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas.
Cell Cycle
December 2007
Department of Biology, Boston College, Chestnut Hill, Massachusetts 02467, USA.
Cyclin-dependent kinase (cdk) inhibitors have the potential to induce growth arrest and apoptosis in cancer cells. The genes encoding cdks involved in G1-S progression are often amplified in B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL). Here, we evaluated the in vitro cytotoxic activity of the cdk2 inhibitor CVT-313 against several human DLBCL cells.
View Article and Find Full Text PDFPrognosis and treatment outcome in patients with acute myeloid leukemia with t(8;21)(q22;q22).
Adv Ther
January 2008
Department of Medicine, Division of Hematology/Oncology, Chang Gung Memorial Hospital-Chiayi, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan.
Article Synopsis
- * In this study of 22 patients with t(8;21)(q22;q22), factors such as higher platelet counts, lower white blood cell counts, and hematopoietic stem cell transplantation (HSCT) as postremission therapy were linked to better OS.
- * The results suggest that treatment plans for AML patients with the t(8;21) genetic change should prioritize HSCT in postremission therapy to improve patient outcomes. *
[Cytogenetics and acute non-lymphoblastic leukemias. Value of short-term cultures].
Nouv Rev Fr Hematol (1978)
August 1983
Normal and abnormal results of chromosome studies performed on 101 acute nonlymphoblastic leukemia (ANLL) patients were compared according to the bone marrow and/or blood cell culture times. A higher proportion of abnormal karyotypes was observed after culture than on direct preparations in acute promyelocytic leukemia and in acute myeloblastic leukemia with t(8-21) translocation; in some cases the chromosome abnormality seen after culture was not detected with the direct technique. No clear-cut differences in chromosome studies resulted when the differing techniques were applied to other forms of ANLL.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!